Unlike traditional antibody-drug conjugates (ADCs) that deliver cytotoxic agents to obliterate malignant cells, AOCs deploy nucleic acid sequences such as antisense oligonucleotides, small interfering RNAs, or splice-switching oligonucleotides. These payloads can selectively modulate gene expression, offering disease-modifying potential that transcends symptom management. This precision dramatically lowers off-target interactions, reducing adverse effects often associated with broader pharmacologic interventions. The ability of AOCs to enact gene-level corrections positions them at the forefront of next-generation therapeutics aimed at inherited and acquired genetic diseases.

Despite their remarkable promise, the clinical translation of AOCs is moderated by several critical challenges, paramount among them being the identification of optimal target receptors that facilitate effective cellular entry. The transferrin receptor 1 (TfR1), a gateway deeply explored for its natural role in iron uptake via receptor-mediated endocytosis, has been the primary focus of AOC development to date. Its robust endocytic capacity and widespread tissue expression make it an appealing vector for AOC delivery. Indeed, recent successes with TfR1-targeted AOCs in disorders like Duchenne muscular dystrophy (DMD) underscore its value, as evidenced by multiple candidates advancing into late-stage clinical trials.

However, TfR1 is far from a universal solution, as its expression profile and internalization dynamics limit the scope of AOC applicability. Consequently, ongoing research rigorously investigates alternative targets and seeks to refine antibody engineering strategies that enhance delivery efficiency. The endocytic kinetics of a receptor—its ability to internalize and traffic antibody-bound cargo to intracellular compartments—emerges as a pivotal determinant in this quest. Careful screening and validation of novel receptors with favorable endocytosis characteristics could unlock broader tissue targeting, especially for extrahepatic indications that have historically faced delivery bottlenecks.

Antibody format selection further intricate this therapeutic paradigm. Choices ranging from full-length immunoglobulins to smaller antibody fragments or engineered bispecific antibodies can profoundly influence AOC pharmacokinetics, tissue penetration, and internalization. Full-length IgGs tend to exhibit prolonged circulation half-lives but may face steric hindrance or suboptimal endocytic rates, whereas antibody fragments or bispecifics grant enhanced tissue accessibility and dual-targeting capabilities but often require modifications to stabilize their pharmacodynamic profiles. The delicate balance between molecular size, binding affinity, and immune system engagement is central to maximizing therapeutic windows.

Linker chemistry also assumes a crucial role in AOC design, where the conjugation interface between antibody and oligonucleotide dictates not only the stability of the construct in systemic circulation but also the controlled release of the nucleic acid payload within target cells. Various cleavable and non-cleavable linker motifs have been explored, each with nuances affecting the bioavailability and intracellular trafficking of the oligonucleotide. Optimizing linker properties to resist premature degradation while facilitating efficient cytosolic delivery remains a fundamental engineering challenge.

Parallel to antibody and linker optimization are advances in nucleic acid chemistry aimed at augmenting delivery and biological activity of oligonucleotide payloads. Chemical modifications such as phosphorothioate backbones, 2’-O-methyl, and locked nucleic acid (LNA) analogs bolster nuclease resistance, enhance binding affinity to target RNA, and modulate immune recognition. These strategic nucleotide alterations profoundly impact pharmacodynamics and contribute to the overall efficacy and safety profile of AOCs.

The cumulative insights from dissecting the structure-activity relationships across antibody engineering, linker design, and oligonucleotide modification illuminate a complex yet promising blueprint for fine-tuning AOC therapeutics. These intertwined parameters influence biodistribution, cellular uptake, endosomal escape, and ultimately the capacity to achieve potent gene modulation within diverse tissues.

Looking forward, the development trajectory of AOCs is poised to expand through innovative modalities. Emerging bispecific antibodies capable of simultaneously engaging multiple targets or receptors offer prospects for enhanced specificity and improved endocytic routing. Peptide conjugation strategies may complement antibody-mediated delivery by providing alternative or synergistic targeting mechanisms. Furthermore, the integration of cutting-edge gene editing tools such as CRISPR-Cas systems conjugated within AOC frameworks presents an avenue for permanent genetic correction rather than transient gene modulation.

Artificial intelligence (AI) and machine learning approaches are increasingly being employed to accelerate AOC design by predicting optimal antibody-oligonucleotide combinations, linker chemistries, and modification patterns. These computational tools analyze vast molecular data sets, enabling rational design and iterative refinement with unprecedented speed and accuracy. Such data-driven strategies promise to surmount current limitations, bringing bespoke AOC candidates from bench to bedside more rapidly.

The promise of AOCs to transcend the hepatic delivery confines that have historically hampered nucleic acid therapeutics marks a significant milestone in precision medicine. By leveraging antibody specificity and refined oligonucleotide design, these conjugates pave the way for systemic targeting of diseases affecting muscle, central nervous system, and other extrahepatic organs. Clinical strides exemplified by ongoing trials in muscular dystrophy highlight the maturation of this technology from experimental concept to viable therapeutic platform.

However, realizing the full potential of AOCs will require sustained interdisciplinary collaboration, integrating immunology, molecular biology, chemistry, and computational sciences. Equally important will be comprehensive clinical evaluation to understand long-term safety, optimal dosing regimens, and potential immunogenicity concerns arising from repeated administration.

In summary, antibody-oligonucleotide conjugates represent a compelling frontier in gene therapy, blending molecular precision with targeted delivery to surmount previously intractable challenges. The continued refinement of target selection, antibody engineering, linker chemistry, and nucleic acid modifications, empowered by AI-driven design and novel bioconjugation strategies, portends a transformative impact on the treatment landscape for genetic disorders. As this field matures, it is poised not only to expand therapeutic options but also to redefine paradigms of drug delivery and disease management in the twenty-first century.

Subject of Research: Antibody-oligonucleotide conjugates (AOCs) for targeted gene therapy and extrahepatic delivery strategies.

Article Title: Research progress and development strategies of antibody-oligonucleotide conjugates.

Article References:
Fan, W., Luan, W., Yu, W. et al. Research progress and development strategies of antibody-oligonucleotide conjugates. Gene Ther (2026). https://doi.org/10.1038/s41434-026-00621-5

Image Credits: AI Generated

DOI: 25 May 2026

Keywords: Antibody-oligonucleotide conjugates, gene therapy, extrashepatic delivery, transferrin receptor 1, antibody engineering, linker chemistry, nucleic acid modification, bispecific antibodies, peptide conjugation, gene editing, artificial intelligence.

Traditional nanoplatforms have long been hampered by their inability to actively penetrate tumor masses, resulting in limited diffusion and consequently poor therapeutic outcomes. This limitation arises primarily from the dense extracellular matrix and high interstitial fluid pressure characteristic of solid tumors, which serve as physical and biochemical barriers to nanoparticle infiltration. Recognizing these obstacles, Professor Yingfeng Tu and his colleagues sought to design a dynamic nanotherapeutic system that could actively propel itself, thereby overcoming the diffusion constraints typical of passive nanomedicines.

The core of their design lies in a biocompatible framework composed exclusively of endogenous proteins—glucose oxidase and ferritin—crosslinked via glutaraldehyde. This elegant construction yields nanoparticles that harness enzymatic activity to generate self-propulsive forces. Specifically, glucose oxidase catalyzes the oxidation of glucose to gluconic acid and hydrogen peroxide, creating local chemical gradients that propel the nanoparticles and facilitate enhanced diffusion within tumor tissues. The use of purely protein-based components not only ensures minimal systemic toxicity but also allows for efficient biodegradation, addressing a common concern in nanomedicine regarding persistence and off-target effects.

Ferroptosis, the form of programmed cell death triggered by iron-dependent lipid peroxidation, has emerged as an effective mechanism for eliminating cancer cells resistant to apoptosis. By integrating ferritin—an iron storage protein—into the nanoparticle, the researchers successfully amplified ferroptotic pathways. Once inside the tumor microenvironment, intracellular uptake of these self-propelled particles initiates ferroptosis, disrupting cellular membranes and impairing essential organelles, including mitochondria and lysosomes. This multi-organelle targeting strategy enhances cytotoxicity and suppresses tumor proliferation more effectively than single-targeted therapies.

Over two years, the team conducted comprehensive assessments of their nanoinducer’s physicochemical properties, motion dynamics, and chemotactic behaviors. Using advanced imaging and tracking techniques, they observed that the nanoinducer actively navigates chemical gradients within tumor tissues, enabling deeper infiltration compared to conventional nanoparticles that rely solely on diffusion. This self-motility translates into homogeneous distribution throughout the tumor mass, maximizing therapeutic payload delivery and minimizing the survival of hypoxic or drug-resistant tumor regions.

In vitro experiments demonstrated pronounced cell death in multiple cancer cell lines upon treatment with the nanoinducer, confirming its potent ferroptosis-inducing activity. Subsequent in vivo studies in murine tumor models revealed significant tumor shrinkage without evident systemic toxicity, highlighting the platform’s translational potential. The authors emphasize that this approach not only boosts antitumor efficacy but also mitigates the side effects commonly associated with chemotherapy and radiotherapy, positioning the nanoinducer as a promising candidate for future clinical applications.

Biocompatibility stands as a defining feature of this technology. The exclusive use of endogenous proteins circumvents immune clearance and adverse reactions, which often complicate nanotherapeutic administration. Given the nanoinducer’s biodegradability, metabolic clearance is efficient, diminishing risks of accumulation and long-term toxicity. This contrasts sharply with many synthetic nanoparticles that persist in the body and can elicit off-target effects, thereby limiting their therapeutic window.

The dual-component system capitalizes on synergistic mechanisms. Glucose oxidase-driven self-propulsion enhances penetration, while ferritin-mediated ferroptosis ensures effective cancer cell eradication. This synergy addresses two critical limitations of current nanotherapeutics: shallow tumor penetration and insufficient induction of programmed cell death pathways. The thoughtful molecular engineering embodied in this platform facilitates active motion and effective biochemical action, a combination rarely achieved in the nanomedicine field.

Looking ahead, the research team is committed to expanding the applicability of their nanoinducer to other malignant cancer types, including notoriously treatment-resistant non-small cell lung cancer. Rigorous preclinical studies and optimization of dosing regimens are underway to support eventual clinical translation. The overarching goal is to develop a versatile, biocompatible nanotherapeutic that can be tailored to diverse oncological contexts, thereby transforming the standard of care.

This pioneering study provides a compelling proof of concept for the integration of self-propulsion and ferroptosis induction in a single, protein-based nanotherapeutic. By surmounting the intrinsic barriers of tumor microenvironments, this technology sets a new benchmark in the targeted delivery of anticancer agents. As the field of nanomedicine advances, such sophisticated platforms are poised to deliver unprecedented precision and efficiency in cancer therapy, with the potential to improve patient survival and quality of life substantially.

The work has been published in the International Journal of Extreme Manufacturing, underscoring the interdisciplinary nature combining nanotechnology, biochemistry, and oncology. The study also highlights the transformative potential of extreme manufacturing techniques in creating multifunctional, dynamic nanostructures tailored for complex biological challenges. The collaboration between engineers, chemists, and clinicians is crucial for driving innovations that cross the boundaries between materials science and medicine.

In sum, the self-propelled ferroptosis nanoinducer from Southern Medical University represents an exciting leap forward in nanotherapeutic design. Grounded in rigorous scientific principles and enabled by novel manufacturing strategies, this platform offers hope for overcoming the long-standing obstacles of tumor penetration and drug resistance. As research continues to unfold, the convergence of active nanomotion and programmed cell death induction heralds a new era in cancer therapeutics.

Subject of Research: Nanotherapeutics; Ferroptosis; Cancer Therapy; Nanoparticle Penetration

Article Title: Self-propelled ferroptosis nanoinducer for enhanced cancer therapy

News Publication Date: 24-Jan-2025

Web References:
https://iopscience.iop.org/journal/2631-7990
http://dx.doi.org/10.1088/2631-7990/ada838

Image Credits: By Wenxin Xu, Hao Tian, Yanzhen Song, Hanfeng Qin, Junbin Gao, Yichi Chen, Weichang Huang, Lin Lin, Haixin Tan, Yicheng Ye, Xiaoting Zhang, Daniela A Wilson, Guang Yang, Fei Peng and Yingfeng Tu

Keywords: Ferroptosis, Nanoparticles, Cancer Therapy, Self-propelled Nanotherapeutics, Tumor Penetration, Biocompatibility, Glucose Oxidase, Ferritin, Programmed Cell Death, Nanomedicine, Tumor Microenvironment, Enzymatic Propulsion